What is CStone Pharmaceuticals?
CStone Pharmaceuticals, established in 2015 and publicly traded on the Hong Kong Stock Exchange (HKEX: 2616), is a biopharmaceutical firm dedicated to the research, development, and commercialization of novel treatments for cancer patients globally. The company has cultivated a robust pipeline comprising 15 drug candidates, with a strategic focus on combination therapies within the immuno-oncology space. CStone's operational framework is guided by a seasoned management team possessing extensive expertise in drug innovation, clinical trials, and market deployment. To date, CStone has achieved regulatory approval for four of its drugs, resulting in eight distinct drug approvals, highlighting its progress in bringing critical therapies to market.
How much funding has CStone Pharmaceuticals raised?
CStone Pharmaceuticals has raised a total of $262M across 1 funding round:
Series A
$262M
Series A (2018): $262M, investors not publicly disclosed
What's next for CStone Pharmaceuticals?
The substantial enterprise-level funding and recent strategic investment signal a critical growth phase for CStone Pharmaceuticals. This capital infusion is expected to accelerate the development and commercialization of its promising immuno-oncology and precision medicine pipeline. The company's strategic emphasis on combination therapies positions it to address complex unmet medical needs in oncology. With a clear vision to become a globally recognized biopharmaceutical leader, CStone is poised to expand its reach and impact, bringing innovative cancer treatments to patients worldwide.
See full CStone Pharmaceuticals company page
